

Cerbios Pharma and XSpray agree to establish a long-term partnership on the use of XSpray's *RightSize*TM technology

Lugano (Switzerland) – Stockholm (Sweden) - Cerbios-Pharma SA (from now on Cerbios) and XSpray Microparticles AB (from now on XSpray) have signed a letter of intent to develop a long-term, mutually beneficial collaboration whereby XSpray will be the preferred technology provider and Cerbios will be the preferred manufacturer for the joint development of HPAI (High Potency Active Ingredients) products with unique characteristics.

The formulation and manufacturing abilities of XSpray's *RightSize*TM technology offer the opportunity to improve drug substances through various strategies, enabling full control over particle design and production – simplifying drug formulation, extending delivery options and allowing the addition of innovative properties that truly benefit patients.


The *RightSize* technology uses supercritical fluid as an antisolvent for controlled precipitation of an active pharmaceutical ingredient/drug substance.

RightSize technology not only provides a superior process to traditional methods it can also be effectively scaled from discovery scale up to production volumes, making it an important breakthrough in the manufacture of pharmaceutical particles using supercritical fluid technology. One of the advantages of this technology is that the moderate temperatures used make it ideal for particle size reduction of thermolabile compounds.

The development phases will be provided by XSpray in Stockholm , while the cGMP production for clinical and/or commercial at Cerbios in Lugano

"We are enthusiastic about this partnership with XSpray. Access to RightSize technology will strengthen our API development and manufacturing competency for third parties", says Dr. Gabriel Haering, CEO of Cerbios.

"Through the use of this innovative technology for HPAI at a first stage, Cerbios will be able to offer a unique capability, enabling the generation not only of particles having narrow Particle Size Distribution (PSD) but also different crystal forms and/or polymorphs up to the full control of particle design, including solid state form .



In combination with other technologies available at Cerbios it will generate Intellectual Property that will definitely help our partners in their success."

"XSpray's RightSize technology is a perfect complement to the considerable knowledge and extensive experience of Cerbios-Pharma in the field of manufacturing and handling of HPAI".

Commented XSpray's CEO, Dr. Per Andersson.

"We are very pleased with this collaboration, Cerbios has an excellent track record with over 30 years of experience in process development and manufacturing from early stage to commercial supply."

About Cerbios-Pharma SA

Cerbios is a privately held self-financed company located in Lugano (Switzerland) specialized in the development and manufacturing of chemical and biological APIs for partners world-wide.

APIs made by Cerbios cover small molecules (Chemical Division), biopharmaceuticals including Monoclonal Antibodies, Recombinant Proteins and Probiotics (Biological Division).

Services for third parties under exclusive manufacturing are offered in the area of HPAIs for the Chemical Division and Monoclonal Antibodies and Recombinant Proteins for the Biological Division.

Full CMC support is provided to partners in order to provide them with the supply of cGMP clinical batches, registration/validation material and APIs from commercial manufacturing. Paramount to this is the supply of all documentation required for a successful registration.

About XSpray Microparticles AB

XSpray is a technology company with in-depth knowledge of supercritical fluid technology, solid state properties, formulation science and the drug development process.

The company was created in 2003 as CENS Delivery AB.

In February 2007 the company name was changed to XSpray to reflect the change in focus from research to commercialization of the technology for use in the production of high quality pharmaceutical particles.

In 2009, XSpray doubled the size of its service lab and increased its personnel resources to meet growing interest in the company's offering.

XSpray's GMP production facility for classical APIs (non HPAIs) was opened in mid 2009.

XSpray is part of the Karolinska Development

For further information please contact:

Cerbios-Pharma SA

Andrea Tam
Director Business Development
andrea.tam@cerbios.ch

XSpray Microparticles AB

Karen Frost
Marketing Director
Karen.frost@xspray.com

Cerbios-Pharma SA
Via Pian Scairolo 6
CH-6917 Barbengo / Lugano
Switzerland

Phone +41 (0) 91 985 63 11
Fax +41 (0) 91 985 63 25
Email info@cerbios.ch

www.cerbios.ch